WHO Grade II or III meningioma were excluded. Those with clinical and imaging features of a benign meningioma involving the parasagittal or parafalcine region and no history of previous cancer were also included in the study. Seven patients with 9 tumors that had no imaging follow-up were excluded, yielding 65 patients with 90 tumors for analysis. Of the 65 patients, 16 had MRI followup without clinical follow-up. We excluded these patients from the clinical outcomes analysis but included them in the imaging outcomes analysis. Figure 1 shows the patient groups' composition. Some patients groups' had more than one discrete PSPF meningioma. In terms of local tumor control, these tumors were analyzed separately. The patients' mean age was 56.9 years (range 24-83 years). The median preradiosurgery KPS score was 80 (range 40-100). The most common clinical presentations were headache in 19 patients (29%), motor deficit in 15 patients (23%), sensory deficit in 11 patients (17%), and seizure in 11 patients (17%). Table 1 summarizes the characteristics of the patient population.
Tumor Characteristics
Of the 90 meningiomas included for imaging analysis, 53 were parasagittal (58.9%) and 37 were parafalcine (41.1%). The median initial tumor volume was 3 cm . Preradiosurgery treatment included resection in 72 tumors (80%), embolization in 4 tumors (4.4%), and radiation therapy in 18 tumors (20%). An increase or decrease in tumor size was defined as a 15% increase or decrease in tumor volume. Tumor control was defined as decreased or unchanged tumor volume. Tumor attributes are detailed in Table 2 .
The GKS Technique
The GKS approach at our institution has been previously described. 25 For the current series, radiosurgery treatment parameters are described in Table 3 . The Leksell Gamma Knife Model U was used from 1991 until 2001, when the Model C was instituted. In 2006, the Gamma Knife Perfexion was used. The median parameters were prescription dose 15 Gy (range 10-20 Gy), isodose line 40% (range 30%-55%), isocenters 5 (range 1-24), and treatment volume 3.7 cm 3 (range 0.7-33.1 cm ). More than one radiosurgery treatment was performed in 33 patients (36.7% of tumors).
Post-GKS Follow-Up
The MRI and clinical follow-up was obtained every 6 months for 2 years, with subsequent annual follow-up starting at 2 years post-GKS. All follow-up imaging was reviewed by both a neuroradiologist and a neurosurgeon at our institution. Because our institution is a tertiary referral center, clinical follow-up was obtained through a combination of outpatient visits to our clinic and inpatient 
Fig. 1.
Chart showing composition of the groups of patients included for analysis. All patients with MRI follow-up (n = 65) were included in the imaging outcomes analysis, whereas only patients with clinical followup (n = 49) were included in the clinical outcomes analysis. (20) admissions to our hospital, outpatient visits from referring primary care physicians, and inpatient admissions to referring hospitals. For the 65 patients (90 tumors) with imaging follow-up, the duration was a mean of 56.6 months, median 48.6 months, and range 6.1-199.5 months. For the 49 patients (68 tumors) with clinical follow-up, the duration was a mean of 70.8 months, median 58.5 months, and range 6.5-193.4 months.
Statistical Analysis
All statistical analyses were conducted using IBM SPSS 20 software. A Kaplan-Meier plot was constructed to assess PFS. Univariate and multivariate Cox proportional hazards model analyses were used to evaluate factors associated with PFS, including patient age, sex, tumor location, prescription dose, initial tumor and treatment volumes, preradiosurgery therapies, and preradiosurgery KPS score. Variables with a p value of less than 0.05 in univariate analyses were enrolled into a subsequent multivariate analysis. All statistical tests were 2-tailed, and a p value less than 0.05 was deemed statistically significant. We used the number of tumors as the denominator when describing tumor control and PFS, and we used the number of patients as the denominator when describing clinical outcomes. The Student t-test was used to determine differences in patient, tumor, and treatment characteristics between PSPF meningiomas.
Results

Progression-Free Survival and Predictors of Tumor Control
The mean overall PFS was 88.8 months and the median was 75.6 months. The PFS was significantly higher (p = 0.014) in parasagittal meningiomas, mean 104.2 months and median 97.4 months, than in parafalcine meningiomas, mean 63.7 months and median 50.8 months. Figure 2 shows the PFS over time. The t-test results did not identify any difference in patient age, tumor volume, or prescription dose between PSPF meningiomas.
Univariate Cox regression analysis identified parasagittal location, no preradiosurgery resection, higher preradiosurgery KPS score, and younger age as significant predictors of PFS. Parasagittal location, no preradiosurgery resection, and younger age were independent predictors of PFS in the multivariate analysis. Table 4 shows the Cox regression analysis for all analyzed variables. Tumor control was achieved in 61 tumors (67.8%) and 47 patients (72.3%). The actuarial tumor control rate for parasagittal meningiomas, 92% at 3 years and 80% at 5 years, was higher than the tumor control rate for parafalcine meningiomas, 75% at 3 years and 54% at 5 years. The overall tumor control rate for PSPF meningiomas at 3 and 5 years was 85% and 70%, respectively. For patients without prior treatment including resection, embolization, and radiotherapy, actuarial tumor control rates at 3 and 5 years were both 93% for PSPF meningiomas.
Clinical Outcomes Following Radiosurgery
Neurological function was improved in 20 patients (40.8%), unchanged in 27 patients (55.1%), and deteriorated in 2 patients (4.1%). The KPS score following radiosurgery was a median of 90 (range 40-100). Change in KPS was a median of 0 (range -20 to 20). Postradiosurgery seizures were observed in 7 patients (14.3%), including 3 (6.1%) without seizures prior to radiosurgery. New-onset seizures were associated with decline in neurological function in 1 patient. Postradiosurgery death occurred in 11 patients (22.4%). Although no deaths were directly attributable to radiosurgery, the causes of death were tumor progression in 2 patients (4.1%), unrelated causes in 4 patients (8.2%), and unknown in 5 patients (10.2%).
Postradiosurgery Complications
New long-term encephalomalacia in a region of postradiosurgery T2-weighted MRI changes was evident in 5 patients (7.7%) on follow-up imaging. Temporary new or worsened peritumoral edema was seen in 13 patients with MRI follow-up only (20%) and in 10 patients with both clinical and MRI follow-up (20.4%). Postradiosurgery peritumoral edema was symptomatic in 4 patients (8.2%), including 3 patients with new-onset seizures and 1 with neurological decline. Symptomatic postradiosurgery edema was temporary in 3 patients (6.1%) and permanent in 1 (2%). These patients were treated with corticosteroids and/or anticonvulsants as appropriate. There was no evidence of postradiosurgery brain necrosis, sagittal sinus thrombosis, or cortical vein thrombosis.
Further Treatment After Radiosurgery
Resection following radiosurgery was performed on 12 tumors (13.3%) in 8 patients (12.3%). Indications for surgery included tumor progression for 11 tumors (12.2%) in 7 patients (10.8%) and cerebral edema refractory to steroids for 1 tumor (1.1%) in 1 patient (1.5%). All tumors resected after failed radiosurgery were histologically confirmed to be WHO Grade I meningiomas. No patients received embolization, fractionated radiotherapy, or chemotherapy after radiosurgery.
Discussion
Parasagittal and parafalcine meningiomas are frequently encountered lesions, comprising up to 30% of all intracranial meningiomas. 16 Current treatment options include microsurgical resection, fractionated radiation therapy, and radiosurgery. The optimal management strategy for PSPF meningiomas remains controversial because both surgical and nonsurgical options frequently fail to provide definitive treatment. Additionally, any therapy of these lesions is associated with potential injury to critical surrounding venous structures.
Tumor Resection
Resection of PSPF meningiomas has traditionally been the first-line treatment.
3 Unfortunately, the inherent venous anatomy surrounding these lesions commonly presents a barrier to safe gross-total resection, especially in the posterior portion of the sagittal sinus where a venous infarct can be particularly devastating. 21 Aggressive resection of PSPF meningiomas is technically challenging due to invasion of dural venous sinuses and involvement of bridging cortical veins, which drain into these large sinuses. Sacrifice or complex reconstruction of the superior sagittal sinus is advocated by some neurosurgeons to increase the degree of resection. 2 However, sinus reconstruction does not always prevent large, catastrophic infarcts. 22 Raza et al. 18 reported a 10% postoperative complication rate and an 11% recurrence rate following microsurgical resection of 61 parasagittal meningiomas. Microsurgery should be considered for larger meningiomas, presentation with motor or sensory deficit, and failure of radiosurgery to control tumor growth. Although resection will remain a mainstay of PSPF meningioma management, it should be noted that meningiomas in this location are associated with relatively high rates of recurrence and increased risk of injury to major venous channels compared with meningiomas located elsewhere. 3, 7, 11 In a recent study the overall 25-year recurrence rate for surgically treated parasagittal meningiomas was 47%.
16 Therefore, it seems clear that surgery alone will not prove sufficient for managing the disease in many patients with PSPF meningiomas.
Radiation Therapy
Fractionated EBRT has historically been used as an adjuvant therapy following subtotal resection. 1 Although EBRT is rarely used as an upfront treatment, several studies have supported its ability to achieve tumor control following subtotal tumor debulking. 9, 19 It should be noted that there is no literature describing the outcomes of EBRT specifically for PSPF meningiomas. Therefore we infer our conclusions from several series including all meningiomas. Condra et al. 5 reported similar tumor control and survival in comparing complete resection without EBRT and subtotal resection with subsequent EBRT. Although EBRT is used more frequently for larger volume and more diffuse meningiomas, there is some over- lap between the characteristics of meningiomas treated with radiosurgery and those treated with EBRT. Due to the increasing popularity of radiosurgery and the paucity of literature, it is difficult to compare radiosurgery and EBRT for PSPF meningiomas. Girvigian et al. 8 found significantly higher rates of symptomatic peritumoral edema following radiosurgery compared with EBRT for convexity and parasagittal meningiomas.
In our cohort of PSPF meningiomas, 20% were treated with EBRT prior to radiosurgery. It is conceivable that these previously irradiated meningiomas were more aggressive than their nonirradiated counterparts, or they may simply have been treatment failures. Over the time encompassed by this study, the WHO has broadened its definition of atypical meningiomas. Therefore, it is possible that some of the presumed WHO Grade I meningiomas included in this study were slightly more biologically aggressive and therefore biased the results in an unfavorable fashion. However, in our study the morbidity rates for meningiomas with or without preradiosurgery EBRT were not significantly different.
Radiosurgical Treatment
Whereas the radiosurgery literature for skull base meningioma is extensive, publications specifically detailing the radiosurgical outcomes for PSPF meningiomas are very limited.
8,10,13 Table 5 summarizes the major radiosurgery series describing the outcomes for PSPF meningiomas. The previous series demonstrate a reasonable rate of tumor control ranging from 67% to 78% at 5 years after radiosurgery. It is noteworthy that these rates of tumor control are typically lower than those afforded by radiosurgery for meningiomas of the skull base. 23 The lower rates of tumor control may well be related to the vascular supply to these tumors and the possibility of recurrence at the margin of the treatment volume, particularly for those patients with prior resection. With radiosurgery in particular, the dural tail of a meningioma is not included in the planned treatment volume; many PSPF meningiomas do have an extensive dural tail.
Nevertheless, the current series and others in the literature do confirm the value of radiosurgery as a minimally invasive primary or adjunctive treatment for PSPF meningiomas. Radiosurgery is not immune to the perils of injuring the neighboring venous anatomy; radiationinduced venous thrombosis and occlusion may result in delayed venous infarcts. 6 The absence of preradiosurgery resection was an independent predictor of PFS (p < 0.001). This is probably due to the larger initial tumor volume prior to resection, suggesting a higher inherent growth rate and more biological aggressiveness. Oya et al. 15 found that meningiomas with an initial diameter larger than 2.5 cm had shorter times to progression than meningiomas that were smaller than 2.5 cm. Neither initial tumor volume nor treatment volume was associated with PFS in our series.
Parasagittal location was independently associated with tumor control (p = 0.031). Whereas the radiosurgical tumor control rate for parasagittal meningiomas has been reported to be lower than for skull base meningiomas, a comparison of radiosurgery treatment success rates between parasagittal and parafalcine meningiomas has not been made in the literature.
14 A potential reason for superior tumor control in parasagittal rather than parafalcine meningiomas may lie in the deeper location of the draining veins for parafalcine meningiomas. This may be analogous to deep-seated arteriovenous malformations, which often have deep draining veins and make radiosurgery more prone to complications and less likely to result in successful obliteration. 17, 26 The PSPF meningiomas also have been reported to have higher rates of radiosurgery-induced peritumoral edema than their counterparts located elsewhere. 4 Previous studies have identified several factors including larger tumor volume, increased prescription dose, age older than 60 years, and no preradiosurgery resection as predictors of postradiosurgery peritumoral edema.
8,12
The Role for Radiosurgery Radiosurgery appears to offer a reasonable benefitto-risk ratio for patients with small-to moderate-sized PSPF meningiomas. It can be used as an upfront therapy for treating PSPF tumors that are small to moderate in volume and more closely associated with patent venous structures. Parasagittal meningiomas appear to be more amenable to long-term control with radiosurgery compared with parafalcine ones. Figure 3 demonstrates a patient with a parafalcine meningioma successfully treated at our institution with only GKS.
Radiosurgery does appear to offer stabilization of tumor growth that is superior to the natural history.
14 However, the benefits of radiosurgery must be weighed against the morbidity and mortality rate associated with radiosurgery and tumor progression in failed treatment, which in our series was approximately 12%. Despite our findings, resection remains an integral part of PSPF meningioma management. Initial resection should be considered for large meningiomas, typically greater than 3 cm in diameter and smaller meningiomas that are symptomatic. Postradiosurgery resection should be considered for meningiomas that progress despite prior radiosurgery, especially those that are symptomatic. 13 We believe our study shows that radiosurgery is a valuable treatment option for patients with small-to moderate-sized WHO Grade I PSPF meningiomas. We still favor resection for larger meningiomas and those with diagnostic uncertainty. However, resection need not be complete, particularly if injury to critical venous structures is likely. Subtotal resection followed by radiosurgery is a reasonable approach for many large PSPF meningiomas. In addition, we believe that there is little role for EBRT in well-defined WHO Grade I meningiomas.
Comparisons between microsurgical and radiosurgical series are imperfect and may be subject to significant selection biases. This may result in vastly different patient populations and tumor characteristics between microsurgical and radiosurgical studies. Meningiomas described in surgical series are typically much larger than their counterparts in radiosurgical series. It is therefore not completely fair to directly compare the complication rates between the two treatments. Unfortunately, there are no prospective trials comparing resection, radiation therapy, and radiosurgery for matched cohorts of patients with PSPF meningioma. Resection will undoubtedly continue to play a central role in the management of PSPF meningiomas for which radiosurgery appears to be less effective than for comparably sized skull base meningiomas. 23 
Study Limitations
The shortcomings of this study include lack of a control group not treated with radiosurgery, and the treatment preferences and biases associated with any single-institution study. In particular, the use of radiosurgery followed initial resection in 80% of cases in our series. Thus, the current series reflects a treatment paradigm of initial resection followed by radiosurgery for most patients with PSPF meningiomas. Rarely was radiosurgery used at our institution as the upfront treatment for patients with PSPF meningiomas. Additionally, this study is limited by its retrospective nature and is therefore subject to the same selection bias and confounding factors that plague all retrospective studies. However, until randomized, prospective data are available to establish guidelines for meningioma management, we must continue to rely on a combination of retrospective treatment data (both microsurgical and radiosurgical) and expert opinion to plot the best treatment course for patients harboring meningiomas.
Also, the study does have a relatively small number of patients compared with larger radiosurgery series of patients with meningioma in other neuroanatomical locations. Thus, the statistical power of the analysis is limited. However, it is worth noting that the study does represent a large radiosurgical series for this particular location and is one of only a few series to look at this particular radiosurgical cohort.
Conclusions
Radiosurgery is a reasonable, efficacious option for many PSPF meningiomas. It offers good long-term tumor control with an acceptable adverse effects profile. Radiosurgery can be used as initial and adjunct therapy for PSPF meningiomas with significant sinus invasion, meningiomas that cannot be completely resected, and patients with minimal to no symptoms. Ultimately, current and future treatment of PSPF meningiomas will involve a combination of radiosurgery and microsurgical resection.
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